Physician profile
Angela Preda
NPI 1154956878
$5,448.13
in general payments reported to CMS, 2019-2025
32 companies · $910 in 2025
The $910 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $4,426 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,003 · Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,002.87 |
| Food and Beverage | $2,445.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,876.32 | 2024 | |
| Zimmer Biomet Holdings, INC. | $1,777.31 | 2024 | Advantagerib |
| Davol INC. | $271.13 | 2023-2024 | Progel Applicator Spray Tips |
| Arthrex, INC. | $165.99 | 2024-2025 | |
| Solventum Corporation | $163.23 | 2024 | V.A.C. Veraflo, Promogran Prisma, Activ.A.C. |
| Heron Therapeutics, INC. | $120.98 | 2025 | Zynrelef, Aponvie |
| Medical Device Business Services, INC. | $117.64 | 2024 | Stratafix, Vistaseal |
| Kerecis Limited | $116.73 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Astrazeneca Pharmaceuticals LP | $91.70 | 2025 | Enhertu, Imfinzi, Tagrisso |
| Genzyme Corporation | $65.34 | 2025 | |
| Celgene Corporation | $55.91 | 2025 | Reblozyl |
| Incyte Corporation | $55.01 | 2025 | Pemazyre, Monjuvi, Jakafi |
| Rigel Pharmaceuticals, INC. | $50.60 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Eisai INC. | $50.43 | 2024-2025 | |
| Dilon Technologies, INC. | $45.78 | 2025 | Hemoblast Bellows |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $41.70 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.11 | 2024-2025 | Ninlaro, Alunbrig |
| Janssen Biotech, INC. | $34.98 | 2025 | Darzalex |
| Merck Sharp & Dohme LLC | $32.89 | 2025 | Keytruda, Welireg |
| Emd Serono, INC. | $27.77 | 2025 | |
| Geron Corporation | $27.65 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $27.59 | 2024 | |
| Genentech USA, INC. | $23.62 | 2024 | Lunsumio, Polivy, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2025 | |
| Coherus Oncology, INC. | $20.87 | 2025 | Loqtorzi |
| Agios Pharmaceuticals, INC. | $20.42 | 2025 | Pyrukynd |
| Lilly USA, LLC | $19.38 | 2025 | |
| Adaptive Biotechnologies Corporation | $19.32 | 2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $17.99 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $17.61 | 2025 | |
| Puma Biotechnology, INC. | $15.98 | 2025 | |
| Jazz Pharmaceuticals INC. | $14.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Preda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.